Analgesics⏵
Antiandrogens⏵
Antihistamines⏵
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Monoclonals⏵
Mpro inhibitors⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors⏵
TMPRSS2 inh.⏵
Thermotherapy
Vitamins⏵
More⏵

Other
Feedback
Home
 
Top
..
Results
..
Abstract
..
All HCQ studies
..
Meta analysis
..
Feedback
Home
←
next
study
→
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta
Home Adoption Other Treatments
@CovidAnalysis
 

Various Combinations of Favipiravir, Lopinavir-Ritonavir, Darunavir-Ritonavir, High-Dose Oseltamivir, and Hydroxychloroquine for the Treatment of COVID-19: A Randomized Controlled Trial (FIGHT-COVID-19 Study)

Atipornwanich et al., SSRN Electronic Journal, doi:10.2139/ssrn.3936499, NCT04303299, Oct 2021
Source
PDF
All
Studies
Meta
Analysis
https://c19hcq.org/atipornwanich.html
Mortality 56% Improvement Relative Risk Progression 54% Time to viral- 7% primary Time to viral- (b) 7% primary Progression (b) -150% early Time to viral- (c) 43% early, primary Time to viral- (d) 36% early, primary HCQ  Atipornwanich et al.  LATE TREATMENT  RCT Is late treatment with HCQ + combined treatments beneficial for COVID-19? RCT 200 patients in Thailand (October 2020 - July 2021) Trial compares with another combination of treatments Lower progression with HCQ + combined treatments (p=0.025) c19hcq.org Atipornwanich et al., SSRN Electronic J., Oct 2021 FavorsHCQ Favorsoseltamivir/.. 0 0.5 1 1.5 2+
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020, now with p < 0.00000000001 from 423 studies, used in 59 countries.
Lower risk for mortality, hospitalization, progression, recovery, cases, and viral clearance.
No treatment is 100% effective. Protocols combine treatments.
5,700+ studies for 169 treatments. c19hcq.org
RCT 320 patients in Thailand, showing significantly lower progression with HCQ for moderate/severe patients, and faster viral clearance with mild patients (statistically significant for 800mg). There are two sets of results - for moderate/severe patients, and for mild patients. There was no mortality for mild patients. NCT04303299 (history).
Viral load measured by PCR may not accurately reflect infectious virus measured by viral culture. Porter et al. show that viral load early in infection was correlated with infectious virus, but viral load late in infection could be high even with low or undetectable infectious virus. Assessing viral load later in infection may underestimate reductions in infectious virus with treatment.
Important missing comments or errors? Let us know.
Study covers favipiravir and HCQ.
risk of death, 56.2% lower, RR 0.44, p = 0.07, treatment 7 of 100 (7.0%), control 16 of 100 (16.0%), NNT 11, moderate/severe, HCQ arms vs. non-HCQ arms.
risk of progression, 54.2% lower, RR 0.46, p = 0.02, treatment 11 of 100 (11.0%), control 24 of 100 (24.0%), NNT 7.7, moderate/severe, HCQ arms vs. non-HCQ arms.
time to viral-, 7.1% lower, relative time 0.93, p = 0.51, treatment mean 10.4 (±6.3) n=50, control mean 11.2 (±5.7) n=50, moderate/severe, oseltamivir arms, primary outcome.
time to viral-, 6.9% lower, relative time 0.93, p = 0.47, treatment mean 9.5 (±5.0) n=50, control mean 10.2 (±4.6) n=50, moderate/severe, favipiravir arms, primary outcome.
risk of progression, 150.0% higher, RR 2.50, p = 1.00, treatment 1 of 60 (1.7%), control 0 of 30 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), mild, early treatment result.
time to viral-, 43.3% lower, relative time 0.57, p = 0.04, treatment mean 8.9 (±6.0) n=30, control mean 15.7 (±16.7) n=30, mild, HCQ 800, primary outcome, early treatment result.
time to viral-, 36.3% lower, relative time 0.64, p = 0.09, treatment mean 10.0 (±6.9) n=30, control mean 15.7 (±16.7) n=30, mild, HCQ 400, primary outcome, early treatment result.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Atipornwanich et al., 5 Oct 2021, Randomized Controlled Trial, Thailand, peer-reviewed, 16 authors, study period 19 October, 2020 - 20 July, 2021, dosage 400mg days 1-14, 800mg/day or 400mg/day, this trial compares with another treatment - results may be better when compared to placebo, this trial uses multiple treatments in the treatment arm (combined with oseltamivir/favipiravir and duranivir/ritonavir for moderate/severe, oseltamivir and duranivir/ritonavir for mild) - results of individual treatments may vary, trial NCT04303299 (history).
This PaperHCQAll
M.D Kriangsak Atipornwanich, Associate Professor Subsai Kongsaengdao, M.D Piyathida Harnsomburana, M.D Rienthong Nanna, M.D Chatchawan Chtuparisute, M.D Piamlarp Saengsayan, M.D Kittima Bangpattanasiri, M.D Weerawat Manosuthi, M.D Narumol Sawanpanyalert, M.D Attasit Srisubat, M.D Somchai Thanasithichai, M.D Benchalak Maneeton, M.D Narong Maneeton, Chuthamanee Suthisisang, PhD B Pharm, Jaturong Pratuangdejkul, M.D Somsak Akksilp, Professor Dusit Sujurarat, Hospital Rajavithi, Bangkok Bangkok, Thailand
Various combinations of Favipiravir, Lopinavir-Ritonavir, Darunavir-Ritonavir, high-dose Oseltamivir, and Hydroxychloroquine for the treatment of Covid-19: A randomized controlled trial. (FIGHT-COVID-19 Study)
References
Hata, Koseki, Yamaguchi, Limited inhibitory effects of Oseltamivir and zanamivir on human sialidases, Antimicrob Agents Chemother, doi:10.1128/AAC.00344-08
Hung, Lung, Tso, Triple combination of interferon beta-1b, lopinavirritonavir, and ribavirin in the treatment of patients admitted to hospital with Covid -19: an open-label, randomised, phase 2 trial, Lancet, doi:10.1016/S0140-6736(20)31042-4
Kriangsak, Akksilp, Sawanpanyalert, Srisubat, Thanasithichai et al., Various Combination of Antiviral Treatment of Covid -19 Pneumonia
Shinkai, Tsushima, Tanaka, A Randomized, Phase III Clinical Trial, Infect Dis Ther, doi:10.1007/s40121-021-00517-4
Wang, Zhang, Du, Remdesivir in adults with severe Covid -19: a randomised, doubleblind, placebo-controlled, multicentre trial [published correction appears in, Lancet
DOI record: { "DOI": "10.2139/ssrn.3936499", "ISSN": [ "1556-5068" ], "URL": "http://dx.doi.org/10.2139/ssrn.3936499", "author": [ { "affiliation": [], "family": "Atipornwanich", "given": "Kriangsak", "sequence": "first" }, { "affiliation": [], "family": "Kongsaengdao", "given": "Subsai", "sequence": "additional" }, { "affiliation": [], "family": "Harnsomburana", "given": "Piyathida", "sequence": "additional" }, { "affiliation": [], "family": "Nanna", "given": "Rienthong", "sequence": "additional" }, { "affiliation": [], "family": "Chtuparisute", "given": "Chatchawan", "sequence": "additional" }, { "affiliation": [], "family": "Saengsayan", "given": "Piamlarp", "sequence": "additional" }, { "affiliation": [], "family": "Bangpattanasiri", "given": "Kittima", "sequence": "additional" }, { "affiliation": [], "family": "Manosuthi", "given": "Weerawat", "sequence": "additional" }, { "affiliation": [], "family": "Sawanpanyalert", "given": "Narumol", "sequence": "additional" }, { "affiliation": [], "family": "Srisubat", "given": "Attasit", "sequence": "additional" }, { "affiliation": [], "family": "Thanasithichai", "given": "Somchai", "sequence": "additional" }, { "affiliation": [], "family": "Maneeton", "given": "Benchalak", "sequence": "additional" }, { "affiliation": [], "family": "Maneeton", "given": "Narong", "sequence": "additional" }, { "affiliation": [], "family": "Suthisisang", "given": "Chuthamanee", "sequence": "additional" }, { "affiliation": [], "family": "Pratuangdejkul", "given": "Jaturong", "sequence": "additional" }, { "affiliation": [], "family": "Akksilp", "given": "Somsak", "sequence": "additional" } ], "container-title": [ "SSRN Electronic Journal" ], "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2021, 10, 10 ] ], "date-time": "2021-10-10T12:55:10Z", "timestamp": 1633870510000 }, "deposited": { "date-parts": [ [ 2021, 10, 10 ] ], "date-time": "2021-10-10T12:55:13Z", "timestamp": 1633870513000 }, "indexed": { "date-parts": [ [ 2022, 1, 10 ] ], "date-time": "2022-01-10T12:29:11Z", "timestamp": 1641817751857 }, "is-referenced-by-count": 1, "issn-type": [ { "type": "electronic", "value": "1556-5068" } ], "issued": { "date-parts": [ [ 2021 ] ] }, "language": "en", "member": "78", "original-title": [], "prefix": "10.2139", "published": { "date-parts": [ [ 2021 ] ] }, "published-other": { "date-parts": [ [ 2021 ] ] }, "publisher": "Elsevier BV", "reference-count": 0, "references-count": 0, "relation": {}, "score": 1, "short-container-title": [ "SSRN Journal" ], "short-title": [], "source": "Crossref", "subtitle": [], "title": [ "Various Combinations of Favipiravir, Lopinavir-Ritonavir, Darunavir-Ritonavir, High-Dose Oseltamivir, and Hydroxychloroquine for the Treatment of COVID-19: A Randomized Controlled Trial (FIGHT-COVID-19 Study)" ], "type": "journal-article" }
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0